Free Trial
NASDAQ:ARDS

Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis

Aridis Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 07/7/2025 10:59 AM Eastern

About Aridis Pharmaceuticals Stock (NASDAQ:ARDS)

Key Stats

Today's Range
$0.0001
$0.0001
50-Day Range
N/A
52-Week Range
$0.00
$0.08
Volume
6,847 shs
Average Volume
9,043 shs
Market Capitalization
$5.33 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ARDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARDS Stock News Headlines

Aridis Provides Corporate Update
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Aridis Provides Corporate Update
Aridis Pharmaceuticals Inc (ARDS)
See More Headlines

ARDS Stock Analysis - Frequently Asked Questions

Aridis Pharmaceuticals' stock was trading at $0.0001 at the beginning of 2025. Since then, ARDS stock has increased by 0.0% and is now trading at $0.0001.

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $1.43. The company had revenue of $0.52 million for the quarter.

Aridis Pharmaceuticals (ARDS) raised $28 million in an initial public offering on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aridis Pharmaceuticals investors own include VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dare Bioscience (DARE), BioCardia (BCDA), Moleculin Biotech (MBRX), SCYNEXIS (SCYX) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/10/2021
Today
7/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARDS
CIK
1614067
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
50,388,000
Market Cap
$5.33 thousand
Optionable
Not Optionable
Beta
11.59
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ARDS) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners